Evidence map›Paper›PMID 35316924›Full record

ArticleArchives of medical science : AMS2022

Type 2 diabetes control and complications and their relation to serum magnesium level.

Khaled Alswat

Abstract read
In one paragraph

Article in Archives of medical science : AMS, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Magnesium Level and Related Factors in Type 2 Diabetes Mellitus: A Cross-Sectional StudyEndocrine, metabolic & immune disorders drug targets · 2026
    Article
  3. Article
  4. Article
  5. Chronic MgCells · 2023
    Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Khaled AlswatDepartment of Medicine, Taif University, Taif, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Type 2 diabetes (T2D) is a growing health problem nationally and worldwide. Magnesium is an important mineral that is essential for a wide range of metabolic reactions. Here, our primary goal was to determine the prevalence of hypomagnesemia and its relationship to glycemic control, cardiovascular markers, and T2D-related complications. Material and methods: A cross-sectional study was performed from September 2015 to March 2017 including adult patients with T2D who attended the Endocrine and Diabetes Center, Taif, Saudi Arabia. Those with known hypomagnesemia, patients with type 1 diabetes, gestational diabetes, patients with end-stage renal disease, and those on magnesium supplementations were excluded. Those with a serum magnesium level < 0.7 mmol/l were considered to have hypomagnesemia. Otherwise, patients were considered to have a normal serum Mg level. Results: A total of 285 patients with a mean age of 59.4 ±12.7 years were enrolled. The majority of patients were female, with long-standing T2D, with a mean body mass index in the obesity category, and most of them had comorbid conditions. Twenty-eight percent of the screened T2D patients had hypomagnesemia and this group were more likely to have a bachelor degree ( Conclusions: Almost one-third of the screened T2D patients have hypomagnesemia. Hypomagnesemia was associated with the treatment modalities, worse glycemic control, and with peripheral artery disease.

Indexed as

glycemichypomagnesemiamagnesiumtype 2 diabetes

Identifiers

PMID35316924
PMCPMC8924817

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.